Evidence map›Paper›PMID 33959850›Full record

ReviewCancer metastasis reviews2021

The comprehensive landscape of miR-34a in cancer research.

Sijing Li, Xiaohui Wei, Jinyong He, Quanquan Cao, Danyu Du, Xiaoman Zhan, Yuqi Zeng, Shengtao Yuan, Li Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer metastasis reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  6. Molecular insight into the therapeutic potential of miR-34a in retinoblastoma.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sijing LiNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Xiaohui WeiSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
Jinyong HeNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Quanquan CaoMARBEC, Université Montpellier, UM-CNRS-IRD-IFREMER, cc 092, Place E. Bataillon, 34095, Montpellier Cedex 05, France.
Danyu DuNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Xiaoman ZhanNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Yuqi ZengNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Shengtao YuanJiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China. yuanst@cpu.edu.cn.
Li SunNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China. sunli@cpu.edu.cn.
China Pharmaceutical University · CNAnhui Medical University · CNIfremer · FRNational Center for Drug Screening · CN

Funding

National Natural Science Foundation of China No. 81573456National Natural Science Foundation of China No.81773766National Natural Science Foundation of China No.81872892National Natural Science Foundation of China No.82003811Natural Science Foundation of Anhui Province No. 2008085QH403
6 · The paper itself

Abstract

MicroRNA-34 (miR-34) plays central roles in human diseases, especially cancers. Inactivation of miR-34 is detected in cancer cell lines and tumor tissues versus normal controls, implying its potential tumor-suppressive effect. Clinically, miR-34 has been identified as promising prognostic indicators for various cancers. In fact, members of the miR-34 family, especially miR-34a, have been convincingly proved to affect almost the whole cancer progression process. Here, a total of 512 (miR-34a, 10/21), 85 (miR-34b, 10/16), and 114 (miR-34c, 10/14) putative targets of miR-34a/b/c are predicted by at least ten miRNA databases, respectively. These targets are further analyzed in gene ontology (GO), KEGG pathway, and the Reactome pathway dataset. The results suggest their involvement in the regulation of signal transduction, macromolecule metabolism, and protein modification. Also, the targets are implicated in critical signaling pathways, such as MAPK, Notch, Wnt, PI3K/AKT, p53, and Ras, as well as apoptosis, cell cycle, and EMT-related pathways. Moreover, the upstream regulators of miR-34a, mainly including transcription factors (TFs), lncRNAs, and DNA methylation, will be summarized. Meanwhile, the potential TF upstream of miR-34a/b/c will be predicted by PROMO, JASPAR, Animal TFDB 3.0, and GeneCard databases. Notably, miR-34a is an attractive target for certain cancers. In fact, miR-34a-based systemic delivery combined with chemotherapy or radiotherapy can more effectively control tumor progression. Collectively, this review will provide a panorama for miR-34a in cancer research.

Indexed as

MicroRNAsNeoplasmsAnimalsCell Line, TumorDNA MethylationGene Expression Regulation, NeoplasticHumansPhosphatidylinositol 3-KinasesMicroRNAsMIRN34 microRNA, humanPhosphatidylinositol 3-KinasesDNA methylationDownstream targetsFunctional rolesmiR-34amiR-34b/cPrognostic valueTranscription factors

Identifiers

PMID33959850
OpenAlexW3157744878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.